Topic Review

Journal of Neuro-Oncology

, Volume 108, Issue 1, pp 11-27

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Recent advances in the molecular understanding of glioblastoma

  • Fonnet E. BleekerAffiliated withDepartment of Neurosurgery, H2 247, Neurosurgical Center Amsterdam, Location AMC Email author 
  • , Remco J. MolenaarAffiliated withDepartment of Cell Biology and Histology, Academic Medical Center, University of Amsterdam
  • , Sieger LeenstraAffiliated withDepartment of Neurosurgery, Erasmus Medical CenterDepartment of Neurosurgery, St. Elisabeth Ziekenhuis

Abstract

Glioblastoma is the most common and most aggressive primary brain tumor. Despite maximum treatment, patients only have a median survival time of 15 months, because of the tumor’s resistance to current therapeutic approaches. Thus far, methylation of the O 6-methylguanine-DNA methyltransferase (MGMT) promoter has been the only confirmed molecular predictive factor in glioblastoma. Novel “genome-wide” techniques have identified additional important molecular alterations as mutations in isocitrate dehydrogenase 1 (IDH1) and its prognostic importance. This review summarizes findings and techniques of genetic, epigenetic, transcriptional, and proteomic studies of glioblastoma. It provides the clinician with an up-to-date overview of current identified molecular alterations that should ultimately lead to new therapeutic targets and more individualized treatment approaches in glioblastoma.

Keywords

Glioblastoma Molecular (Epi)genetic Transcriptional Proteomic